Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated bipolar disorder guidelines.

Schaffer A, Parikh SV, Kennedy SH, Milev R, Frey BN, Goldstein BI, Beaulieu S, Alda M, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Bond DJ, Lam RW, Yatham LN.

Bipolar Disord. 2013 May;15(3):338-9. doi: 10.1111/bdi.12055. Epub 2013 Mar 25. No abstract available.

PMID:
23521579
2.

CANMAT Guidelines commentary: where does the evidence come from, and how can we use it for our patients?

Swann AC.

Bipolar Disord. 2013 Feb;15(1):45-9. doi: 10.1111/bdi.12037. No abstract available.

PMID:
23339673
3.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA, Berk M.

Bipolar Disord. 2013 Feb;15(1):1-44. doi: 10.1111/bdi.12025. Epub 2012 Dec 12.

PMID:
23237061
4.

Have the CANMAT bipolar guidelines transmogrified from do matter to can matter?

Malhi GS.

Bipolar Disord. 2013 Feb;15(1):54-7. doi: 10.1111/bdi.12033. No abstract available.

PMID:
23339675
5.

Raising the bar for the evidence in evidence-based guidelines.

Ostacher MJ.

Bipolar Disord. 2013 Feb;15(1):50-3. doi: 10.1111/bdi.12032. No abstract available.

PMID:
23339674
6.

Taiwan consensus of pharmacological treatment for bipolar disorder.

Bai YM, Chang CJ, Tsai SY, Chen YC, Hsiao MC, Li CT, Tu P, Chang SW, Shen WW, Su TP.

J Chin Med Assoc. 2013 Oct;76(10):547-56. doi: 10.1016/j.jcma.2013.06.013. Epub 2013 Aug 8. Review.

7.

Mood stabilizers for patients with bipolar disorder: the state of the art.

Altamura AC, Lietti L, Dobrea C, Benatti B, Arici C, Dell'Osso B.

Expert Rev Neurother. 2011 Jan;11(1):85-99. doi: 10.1586/ern.10.181. Review.

PMID:
21158558
8.

[Methodological approach to inter "guideline" variability in the management of bipolar disorders].

Samalin L, Llorca PM.

Encephale. 2012 Apr;38(2):126-32. doi: 10.1016/j.encep.2011.07.004. Epub 2011 Aug 31. Review. French.

PMID:
22516270
9.

Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders.

Keck PE Jr, Strawn JR, McElroy SL.

J Clin Psychiatry. 2006;67 Suppl 1:8-15. Review.

10.

The Texas implementation of medication algorithms update for treatment of bipolar I disorder.

Perlis RH, Keck PE.

J Clin Psychiatry. 2005 Jul;66(7):818-20. No abstract available.

11.

Special issues in trial design and use of placebo in bipolar illness.

Post RM, Denicoff KD, Leverich GS.

Biol Psychiatry. 2000 Apr 15;47(8):727-32. No abstract available.

PMID:
10773180
12.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.

Beaulieu S, Saury S, Sareen J, Tremblay J, Schütz CG, McIntyre RS, Schaffer A; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force.

Ann Clin Psychiatry. 2012 Feb;24(1):38-55. Review.

PMID:
22303521
13.

Pediatric bipolar disorder: evidence-based psychopharmacological treatments.

Hamrin V, Pachler M.

J Child Adolesc Psychiatr Nurs. 2007 Feb;20(1):40-58. Review.

PMID:
17284237
14.

What constitutes evidence-based pharmacotherapy for bipolar disorder? Part 1: first-line treatments.

Goldberg JF.

J Clin Psychiatry. 2007 Dec;68(12):1982-3. No abstract available.

PMID:
18162032
15.

International Consensus Group on Bipolar I Depression Treatment Guidelines.

Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young AH.

J Clin Psychiatry. 2004 Apr;65(4):571-9. Review. No abstract available.

PMID:
15119923
16.

What is the best treatment for bipolar depression?

Young LT.

J Psychiatry Neurosci. 2008 Nov;33(6):487-8. No abstract available.

17.

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression.

Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders.

World J Biol Psychiatry. 2002 Jul;3(3):115-24. Review.

PMID:
12478876
18.

The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.

Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force.

Ann Clin Psychiatry. 2012 Feb;24(1):6-22. Review.

PMID:
22303519
19.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F.

Bipolar Disord. 2009 May;11(3):225-55. doi: 10.1111/j.1399-5618.2009.00672.x.

PMID:
19419382
20.

Treatments for late-life bipolar disorder.

Aziz R, Lorberg B, Tampi RR.

Am J Geriatr Pharmacother. 2006 Dec;4(4):347-64. Review.

PMID:
17296540

Supplemental Content

Support Center